Physician profile
Robert Menkel
NPI 1003966532
$1,209.40
in general payments reported to CMS, 2019-2025
11 companies · $68.35 in 2025
The $68.35 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $182 · 2021: $118 · 2022: $335 · 2023: $192 · 2024: $203 · 2025: $68.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $443.71 | 2021-2025 | Symplicity G3, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $210.14 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $165.78 | 2020-2023 | Opsumit |
| Novo Nordisk INC | $122.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $93.93 | 2020-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $39.42 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.21 | 2025 | |
| Philips North America LLC | $28.86 | 2023 | |
| Scpharmaceuticals INC. | $28.28 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $19.92 | 2023 | Andexxa |
| Merck Sharp & Dohme LLC | $18.66 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Menkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.